A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants
Active, not recruiting · Phase 1 · NCT06895343
Conditions: Healthy Volunteer
At a glance
- Research payments reported, 2025
- $9,586
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 100
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-701 (drug), Placebo (drug), ABBV-701 (drug), Placebo (drug)
- Dates
- Started 2025-04-03; completion 2026-11
- Results posted
- Not yet
The main objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single ascending doses of ABBV-701 in healthy adult western and Asian participants.
From ClinicalTrials.gov, last updated 2026-03-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $9,586 in research payments for this study in 2025 (10 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $9,586
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.